Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-05-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and best dose of ivermectin in combination with
pembrolizumab and to see how well they they work in shrinking tumors in patients with triple
negative breast cancer that has spread to other places in the body (metastatic).
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Ivermectin may help block the formation of growths that may become cancer. Giving
ivermectin with pembrolizumab may increase the effect of pembrolizumab in shrinking tumors in
patients with triple negative breast cancer.